16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).

      1 , ,
      PharmacoEconomics
      Springer Science and Business Media LLC

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The principle aim of this study was to generate a league table of drugs considered by the Australian Pharmaceutical Benefits Advisory Committee (PBAC) for reimbursement. The table was used to test the hypothesis that decisions made by the PBAC are consistent with the maxim of economic efficiency. In addition, we explored whether the past decisions by the PBAC revealed a threshold incremental cost-effectiveness ratio beyond which the PBAC is not prepared to recommend reimbursement of a drug.

          Related collections

          Author and article information

          Journal
          Pharmacoeconomics
          PharmacoEconomics
          Springer Science and Business Media LLC
          1170-7690
          1170-7690
          2001
          : 19
          : 11
          Affiliations
          [1 ] Centre for Policy and Practice, University of London School of Pharmacy, Tower Hamlets PCG and Barts' and the London NHS Trust, London, UK. bethan.george@ulsop.ac.uk
          Article
          191104
          10.2165/00019053-200119110-00004
          11735677
          cb9bb147-4749-4c64-bf58-d2a9cdd0f373
          History

          Comments

          Comment on this article